Andrey Doronichev, founder and CEO of Bioptic, joined 20,000+ biotech leaders at BIO 2024 in San Diego to talk AI, science, and the future of drug discovery. Here’s what he took away.
Just got back from BIO 2024 in San Diego. 20,000 people. Four packed days. And one big takeaway: the AI race in biotech isn’t coming—it’s here.
I had dozens of conversations with scientists and biotech leaders. Everyone’s thinking about how to bring AI into the loop—not just as a tool, but as a core teammate in discovery. The challenge? Most teams are still stuck riding horses while the winners are building race cars.
At Bioptic, we’re building those race cars. Our platform puts Google-scale AI tools into the hands of any scientist, not just the ones with a $500M R&D budget.
If you're curious how that feels in practice, try it yourself: app.bioptic.io
Let’s go faster.
– Andrey